Skip to main content
. 2016 May 13;11(12):1551–1569. doi: 10.2217/nnm-2016-0007

Figure 5. . In vivo performance of PEG–PBCL filomicelles.

Figure 5. 

(A) In vivo tumor shrinkage obtained in NOD-SCID mice with tumors established from A549 lung cancer cell line. Four injections of PEG–PBCL filomicelles loaded with TAX were given, with each dose 3 days apart. Tumors treated with drug-loaded PEG–PBCL filomicelles shrink 27% in volume from initial size after 13 days, while the untreated control grows by 15%. (B) Comparison of tumor shrinkage obtained after 13 days of treatment. While PEG–PBCL-loaded filomicelles led to lower tumor shrinkage than PEG–PCL counterparts, the TAX dosage was one-fourth of the latter. OCL–TAX at 10 mg/kg could not produce sustained shrinkage, and consequently, the final tumor size was not much smaller than initial size. OCL data from [31]. (C) Mice treated with PEG–PBCL filomicelles loaded with TAX did not exhibit adverse change in thrombocrit, hematocrit or monocyte numbers. The changes were not significant in all three cases, thus underlining the ability of these filomicelles to safely deliver drug to the tumors.